EMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin ComboEMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin Combo
The drug, known as Cholib, received a "positive opinion" from CHMP for two doses of the fenofibrate/simvastatin combination. A positive opinion is a prerequisite to approval by the European Commission, which has 67 days from the date of the opinion to grant approval. International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 28, 2013 Category: Cardiology Tags: Cardiology News Alert Source Type: news
EMA advisory committee gives thumbs-up to fenofibrate/simvastatin combo
The drug, known as Cholib, received a "positive opinion" from CHMP for two doses of the fenofibrate/simvastatin combination. A positive opinion is a prerequisite to approval by the European Commission, which has 67 days from the date of the opinion to grant approval. (Source: theHeart.org)
Source: theHeart.org - June 28, 2013 Category: Cardiology Source Type: news
Statins Plus Exercise: New Study Questions the Combination
Simvastatin 40 mg once daily was shown to attenuate increases in cardiorespiratory fitness in response to exercise training. Here, the lead author discusses details of the study and the clinical implications for primary care practice. (Source: Consultant Live)
Source: Consultant Live - June 17, 2013 Category: Primary Care Source Type: news
Statin Drugs May Increase Risk Of Diabetes
Certain statins - also known as cholesterol-lowering medications - could increase your risk of developing type 2 diabetes, a new study suggests. The risk was most significant in patients taking atorvastatin (Lipitor), rosuvastatin (Crestor) and simvastatin (Zocor), according to the study, published in BMJ. Statins are the most widely prescribed medications for the prevention of cardiovascular events. Generally, these medications are well received, however, a new link to diabetes has been suggested. Previous studies have indicated a 27% elevated risk of diabetes with rosuvastatin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 24, 2013 Category: Consumer Health News Tags: Statins Source Type: news
Risk of Diabetes With Statins Risk of Diabetes With Statins
While one study is reassuring for older patients treated with statins, with researchers finding no evidence of an increased risk of diabetes in acute coronary syndrome patients, the other suggests that the more potent statins, such as rosuvastatin, atorvastatin, and simvastatin, do pose an increased risk compared with pravastatin. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Diabetes warning over use of statins: People who take the drugs are at increased risk of developing condition
They found a 10 per cent extra risk linked to taking simvastatin - the most commonly prescribed anti-cholesterol drug - which rose to 22 per cent for those taking atorvastatin. (Source: the Mail online | Health)
Source: the Mail online | Health - May 24, 2013 Category: Consumer Health News Source Type: news
Two studies address diabetes risks with statins—one good news, one so-so
While one study is reassuring for older patients treated with statins, with researchers finding no evidence of an increased risk of diabetes in acute coronary syndrome patients, the other suggests that the more potent statins, such as rosuvastatin, atorvastatin, and simvastatin, do pose an increased risk compared with pravastatin. (Source: theHeart.org)
Source: theHeart.org - May 23, 2013 Category: Cardiology Source Type: news
Statins May Reduce Exercise Benefits For Obese Adults
Statins, the most widely prescribed drugs worldwide, are often suggested to lower cholesterol and prevent heart disease in individuals with obesity, diabetes and metabolic syndrome, which is a combination of medical disorders including excess body fat and/or high levels of blood pressure, blood sugar and/or cholesterol. However, University of Missouri researchers found that simvastatin, a generic type of statin previously sold under the brand name "Zocor," hindered the positive effects of exercise for obese and overweight adults... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 18, 2013 Category: Consumer Health News Tags: Statins Source Type: news
Cholesterol-lowering drug may reduce exercise benefits for obese adults, MU study finds
(University of Missouri-Columbia) University of Missouri researchers found that simvastatin, a generic type of drug typically prescribed to lower cholesterol and prevent heart disease, hindered the positive effects of exercise for obese and overweight adults. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 15, 2013 Category: Global & Universal Source Type: news
Zocor Side Effects Update: Bernstein Liebhard LLP Comments on New...
The Firm is currently investigating Zocor lawsuits on behalf of individuals who suffered serious Zocor side effects.(PRWeb April 13, 2013)Read the full story at http://www.prweb.com/releases/zocor-lawsuits/zocor-side-effects/prweb10630147.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 14, 2013 Category: Pharmaceuticals Source Type: news
High-dose statins 'raise risk of serious kidney problems'
High-dose statins taken by millions of people are putting them at increased risk of potentially fatal kidney problems, researchers are warning. (Source: Telegraph Health)
Source: Telegraph Health - March 20, 2013 Category: Consumer Health News Tags: rosustatin kidney simvastatin AKI lipitor atorvastatin crestor Source Type: news
Conference report: Niacin/laropripant combination (Tredaptive) associated with increased risk of bleeding and infections
Source: Reuters Health News
Area: News
Reuters Health News has reported that according to data presented at the annual American College of Cardiology scientific meeting, niacin in combination with laropripant (Tredaptive) was associated with statistically significantly higher rates of bleeding (2.5% vs 1.9%), and infections (8.0% vs 6.6%) compared to patients taking simvastatin or simvastatin/ezetimibe. They called the differences unexpected.
Additionally, patients taking Tredaptive also experienced higher rates of serious health problems that researchers said are known side effects of niacin, which included ne...
Source: NeLM - Cardiovascular Medicine - March 12, 2013 Category: Cardiology Source Type: news
Do We Really Need Head-To-Head Comparison Trials With Statins To Improve Cardiac Health?
Actually, not all statins are alike. Clinical studies have shown, and it is accepted by CV experts around the world, that atorvastatin lowers LDL to a significantly greater extent than simvastatin. One might argue, however, that greater lowering of LDL might not be very meaningful in a real world setting, that all that is necessary is to get LDL below a certain threshold to reduce the risk of heart attacks in at-risk patients. That’s a fair point and, with no real world head-to-head clinical data to confirm this, belief that greater LDL lowering is more beneficial is an article of faith. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 1, 2013 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Niacin Adverse Events in HPS2-THRIVENiacin Adverse Events in HPS2-THRIVE
Extended-release niacin and laropiprant added to simvastatin were associated with a significantly increased risk of definite myopathy. Interestingly, the risk of myopathy was significantly higher in randomized patients from China than in patients from Europe. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
HPS2-THRIVE: High myopathy risk with niacin/laropiprant
Extended-release niacin and laropiprant added to simvastatin were associated with a significantly increased risk of definite myopathy. Interestingly, the risk of myopathy was significantly higher in randomized patients from China than in patients from Europe. (Source: theHeart.org)
Source: theHeart.org - February 27, 2013 Category: Cardiology Source Type: news
